SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
189.5 EUR
+4.6 (+2.49%)
We assign a fundamental rating of 4 out of 10 to 56S1. 56S1 was compared to 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. 56S1 is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
Each year in the past 5 years 56S1 has been profitable.
Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
56S1 has a Return On Assets of 3.35%. This is in the lower half of the industry: 56S1 underperforms 61.11% of its industry peers.
56S1 has a worse Return On Equity (6.54%) than 61.11% of its industry peers.
56S1 has a Return On Invested Capital (5.94%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is below the industry average of 13.84%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1 has a Profit Margin of 8.96%. This is in the better half of the industry: 56S1 outperforms 61.11% of its industry peers.
56S1's Profit Margin has declined in the last couple of years.
56S1 has a Operating Margin of 16.63%. This is in the better half of the industry: 56S1 outperforms 66.67% of its industry peers.
In the last couple of years the Operating Margin of 56S1 has declined.
With a decent Gross Margin value of 45.64%, 56S1 is doing good in the industry, outperforming 72.22% of the companies in the same industry.
In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 56S1 has more shares outstanding
The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.18 indicates that 56S1 is not in any danger for bankruptcy at the moment.
56S1 has a better Altman-Z score (4.18) than 83.33% of its industry peers.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
56S1 has a Debt to FCF ratio (6.84) which is comparable to the rest of the industry.
56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
56S1 has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.18 |
ROIC/WACC0.67
WACC8.93%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.05, 56S1 is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
56S1 has a Quick ratio of 0.50. This is in the lower half of the industry: 56S1 underperforms 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.11% over the past year.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
Looking at the last year, 56S1 shows a small growth in Revenue. The Revenue has grown by 7.72% in the last year.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
56S1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.11% yearly.
Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 10.12% on average per year.
EPS Next Y28.28%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
EPS Next 5Y22.11%
Revenue Next Year8.96%
Revenue Next 2Y9.07%
Revenue Next 3Y9.84%
Revenue Next 5Y10.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 43.97 indicates a quite expensive valuation of 56S1.
Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 77.78% of the companies are valued more cheaply.
56S1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.45.
A Price/Forward Earnings ratio of 35.59 indicates a quite expensive valuation of 56S1.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than 72.22% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.46. 56S1 is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.97 | ||
| Fwd PE | 35.59 |
4.2 Price Multiples
56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 77.78% of the companies in the same industry.
61.11% of the companies in the same industry are cheaper than 56S1, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.25 | ||
| EV/EBITDA | 25.63 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 22.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.55
PEG (5Y)10.48
EPS Next 2Y23.34%
EPS Next 3Y22.86%
5. Dividend
5.1 Amount
With a yearly dividend of 0.37%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is slightly below the industry average, which is at 0.76.
With a Dividend Yield of 0.37, 56S1 pays less dividend than the S&P500 average, which is at 2.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
25.41% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.41%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
FRA:56S1 (11/21/2025, 7:00:00 PM)
189.5
+4.6 (+2.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.44B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target238.84 (26.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)-0.26%
PT rev (3m)-0.06%
EPS NQ rev (1m)7.13%
EPS NQ rev (3m)9.76%
EPS NY rev (1m)0.52%
EPS NY rev (3m)0.52%
Revenue NQ rev (1m)0.74%
Revenue NQ rev (3m)5.19%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.97 | ||
| Fwd PE | 35.59 | ||
| P/S | 6.26 | ||
| P/FCF | 49.25 | ||
| P/OCF | 25.25 | ||
| P/B | 4.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.63 |
EPS(TTM)4.31
EY2.27%
EPS(NY)5.32
Fwd EY2.81%
FCF(TTM)3.85
FCFY2.03%
OCF(TTM)7.51
OCFY3.96%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.55
PEG (5Y)10.48
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.18 |
F-Score8
WACC8.93%
ROIC/WACC0.67
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y28.28%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year8.96%
Revenue Next 2Y9.07%
Revenue Next 3Y9.84%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.68%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
What is the valuation status of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.
What is the financial health of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
How sustainable is the dividend of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 3 / 10 and the dividend payout ratio is 25.41%.